Sirio Pharma Opens Gummy Plant in China

Sirio Pharma, a global nutraceutical contract development and manufacturing organization (CDMO), has opened a gummy production plant at its new development and manufacturing facility in Ma’anshan, China, expanding output to 2.4 billion gummies annually.   

The new facility is being built in several phases and will form a center of excellence covering an area of 240,000 m3. The recently completed first phase of the expansion comprises a 26,000 m3 production space and adjunct building designed to accelerate development and manufacturing of gummy formulations for global customers.

With the plant extension, Sirio said it will have more capacity to make innovative products such as liquid filled, center-filled, swirled and multi-colored gummies. The company also produces standard gummy formulation options to be sold in the US and EU. Some of them have vegetarian options including carrageen and pectin, as well as sugar free and low-sugar options.

Rui Yang, CSO of Sirio Pharma said the advantage of operating an integrated site is that it can develop much more custom tailored products while also expediting development timelines and market share for contract services. Management expects “exponential growth” for the gummy lines in 2019, and with the new capacity Yang said it can supply “even the largest of nutraceutical brands.”

In the US and Europe, the company said it sees “significant growth potential” in gummy formulations, as they represent a more consumer friendly dosage form.

Founded in 1993, SIRIO regards itself as the leading global nutraceutical CDMO specialized in developing and manufacturing quality products including softgel, capsule, tablet, powder, gummy, oral liquid, probiotics and other dosage forms. The company has multiple manufacturing sites in China, as well as plants in Europe and marketing teams in the US.